Loading
A phase 2 trial of Abarelix in Prostate cancer, run by PRAECIS Pharmaceuticals Inc., completed.
Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy is a phase 2 interventional study registered as NCT00100243 by PRAECIS Pharmaceuticals Inc., with 22 participants recorded, started 2004-05. Interventions recorded: Plenaxis. Conditions recorded: Prostate Cancer.
Linked to the drug Abarelix because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Abarelix, Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/